US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
TSLA
$370.59
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
TSLA
$370.59
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Femasys Inc. - Common Stock
(NQ:
FEMY
)
2.050
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Femasys Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
September 09, 2024
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently...
From
Femasys Inc.
Via
GlobeNewswire
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
↗
September 09, 2024
Via
Benzinga
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
September 05, 2024
From
Femasys Inc.
Via
GlobeNewswire
Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings)
↗
June 20, 2024
Via
Benzinga
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
August 29, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
August 27, 2024
The Congresswoman representing Georgia’s 7th district in the U.S. House of Representatives toured Femasys’ facilities to gain a better understanding of our advancements for women’s reproductive health
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event
August 19, 2024
Via
ACCESSWIRE
FEMY Stock Earnings: Femasys Misses EPS, Misses Revenue for Q2 2024
↗
August 08, 2024
FEMY stock results show that Femasys missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
August 08, 2024
Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its infertility portfolio
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
June 27, 2024
Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its products
From
Femasys Inc.
Via
GlobeNewswire
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
↗
June 20, 2024
Via
Benzinga
Topics
Stocks
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
June 20, 2024
Via
Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
↗
June 20, 2024
Via
Benzinga
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
June 20, 2024
From
Femasys Inc.
Via
GlobeNewswire
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
↗
June 17, 2024
Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.
Via
Benzinga
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
May 17, 2024
Lee-Sepsick Discussed Company’s FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis
From
Femasys Inc.
Via
GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
May 16, 2024
Lee-Sepsick Discussed Atlanta-Based Biomedical Company’s Women’s Reproductive Health Products
From
Femasys Inc.
Via
GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024
↗
May 09, 2024
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
May 09, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
May 07, 2024
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting
From
Femasys Inc.
Via
GlobeNewswire
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
April 18, 2024
From
Femasys Inc.
Via
GlobeNewswire
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023
↗
March 28, 2024
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
March 28, 2024
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025
From
Femasys Inc.
Via
GlobeNewswire
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
March 21, 2024
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET...
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
March 20, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
March 13, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
March 06, 2024
From
Femasys Inc.
Via
GlobeNewswire
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
February 28, 2024
From
Femasys Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
